Medtronic plc stock gains attention as diabetes spin-off and robotic surgery clearance reshape its outlook
Published on 09/19/2026 at 11:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic plc stock (ISIN IE00BTN1Y115) closed at USD 92.13 on the New York Stock Exchange on September 18, 2026, putting the company’s market value above USD 100 billion and leaving the shares roughly midway between the 52-week low of USD 73.31 and the high of USD 106.33 per recent price data.
Exchange offer advances diabetes spin-off
According to The Globe and Mail on September 18, 2026, Medtronic launched an exchange offer on September 14, 2026 for up to 225,361,295 newly issued shares of MiniMed Group Inc. common stock in return for outstanding Medtronic ordinary shares, a transaction designed to advance the planned separation of its diabetes-focused MiniMed business and reshape the group’s equity structure.
The same report notes that Medtronic clarified a typographical error in the prospectus governing guaranteed delivery procedures shortly after the offer began, confirming that the guaranteed delivery period for tender documentation expires at 5:00 p.m. New York City time on the second New York Stock Exchange trading day after execution, an adjustment aimed at reducing operational risk and ensuring accurate instructions for shareholders participating in the exchange.
In a related regulatory filing, StockTitan highlighted a Medtronic communication filed under SEC rule 425 on September 18, 2026 describing the offer to exchange up to an aggregate of 225,361,295 newly issued shares of common stock of MiniMed Group Inc. for Medtronic common stock, reinforcing that the separation is being executed via a tax-efficient equity exchange rather than a simple cash sale.
Robotic surgery clearance supports growth narrative
The corporate restructuring comes alongside a product catalyst. As BowTiedBiotech reported on September 19, 2026, the US Food and Drug Administration has cleared Medtronic’s LigaSure RAS Maryland jaw vessel sealer-divider for use with the company’s Hugo robotic-assisted surgery system, expanding the device set available on the platform and enhancing its capabilities in minimally invasive procedures.
According to Simply Wall St on September 18, 2026, the FDA clearance for the LigaSure device on the Hugo system has coincided with a 16.9 percent share price return over the last 90 days, even though the year-to-date share price return remains down 3.4 percent and the five-year total shareholder return is still negative, underscoring that the market is re-rating the stock from a depressed base rather than from record highs.
The same analysis notes that Medtronic’s valuation metrics at this point include a forward price-to-earnings ratio around 13.5, a price/earnings-to-growth ratio near 1.6, a debt-to-equity ratio of approximately 57 percent and an earnings per share growth rate of about 11 percent, with a dividend payout ratio around 76 percent and operational cash flow that supports both investment in growth platforms like Hugo and a steady dividend stream for shareholders.
Fundamentals, guidance and dividend context
From a fundamental perspective, Medtronic remains a large-cap device-based medical therapies provider across cardiac, neuroscience, diabetes and surgical segments. According to StockMarketRanks updated on September 19, 2026, Medtronic had approximately 1.282 billion basic shares outstanding and 1.288 billion diluted shares outstanding as of April 24, 2026, figures that are central to calculating per-share earnings and market capitalization.
Using the closing price of USD 92.13 on September 18, 2026 and the basic shares outstanding as of April 24, 2026, Medtronic’s equity value can be approximated at around USD 118.2 billion, which aligns with the USD 117.92 billion market capitalization cited by Robinhood for the closing state around September 18, 2026 and underlines the company’s status among the bigger names in the global medical technology sector.
Dividend continuity is also part of the story. As Yahoo Finance shows in its options and dividend overview, Medtronic has announced a cash dividend of USD 0.72 per share with an ex-dividend date of September 25, 2026, and Robinhood’s data translate this to a dividend yield of roughly 3.07 percent at recent prices, making the stock a consistent income payer compared with many growth-focused healthcare peers.
On the earnings front, Medtronic recently delivered an upside surprise. According to Zacks on September 9, 2026, Medtronic’s last reported quarter showed earnings of USD 1.45 per share versus the Zacks Consensus Estimate of USD 1.39 per share, representing a positive earnings surprise of 4.32 percent and demonstrating the company’s ability to deliver modest upside against expectations.
The same Zacks overview recalls that in an earlier earnings report for the quarter ending in July 2024, Medtronic posted earnings of USD 1.23 per share compared with the consensus estimate of USD 1.20 per share, a 2.50 percent surprise, indicating that the company has produced earnings modestly ahead of expectations in more than one recent period, even if the exact revenue and margin details for the latest fiscal year are not provided in the current week-filtered data set.
Analyst views and upcoming earnings date
Third-party assessments reflect this mixed picture of restructuring, product progress and steady but not explosive growth. In the diabetes spin-off context, The Globe and Mail cites TipRanks’ Spark AI Analyst rating Medtronic as Outperform, describing the stock as supported by strong and improving fundamentals in margins and free cash flow, a notably upbeat earnings update with raised fiscal year 2027 guidance, and technicals that are supportive of an established uptrend, while noting that valuation is fair rather than aggressively cheap due to the solid dividend.
For investors, the next checkpoint will be the forthcoming earnings release. According to Zacks, Medtronic PLC is scheduled to report its next quarterly earnings on November 17, 2026, with the consensus estimate for the quarter ending in October 2026 standing at USD 1.34 per share and the firm’s model implying a slight negative earnings surprise of around 0.62 percent, suggesting that expectations are anchored to incremental progress rather than a dramatic acceleration.
The combination of a major structural move via the MiniMed share exchange, an expanding robotic surgery portfolio following the FDA’s clearance for the LigaSure device on Hugo, a reliable dividend policy and modest earnings beats against consensus gives Medtronic multiple levers to influence its share price trajectory into the November 17, 2026 earnings date, while the still-negative year-to-date and five-year total shareholder returns highlight that longer-term holders are looking for a more sustained turn in operating performance and valuation.
Stock level and trading metrics
In price terms, the latest Robinhood snapshot indicates that Medtronic shares traded in an intraday range between USD 92.05 and USD 93.03 on September 18, 2026, with the closing print at USD 92.13 representing a decline of USD 0.64 or 0.69 percent on the day compared with the prior close and leaving the stock about 25.4 percent above the 52-week low of USD 73.31 but 13.4 percent below the 52-week high of USD 106.33, a positioning that suggests room both for recovery and for volatility if fundamentals or sentiment disappoint.
Robinhood’s data also show a trading volume of 14.7 million shares on September 18, 2026 against an average daily volume of approximately 8.07 million, indicating that turnover on that day was about 82 percent higher than the typical level and hinting that the combination of the MiniMed exchange offer and the robotic surgery news is attracting more-active trading interest in Medtronic than in quieter periods.
For retail and institutional investors alike, these metrics frame Medtronic as a large, relatively liquid healthcare name with a clear restructuring catalyst, an emerging growth pillar in robotic-assisted surgery and a well-defined upcoming earnings date, while dividend yield, valuation measures and leverage levels provide the numerical context for assessing whether the current USD 92.13 share price adequately reflects both the risks and opportunities embedded in the business.
Medtronic plc stock key data
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Trading venue: NYSE
- Price (as of September 18, 2026): 92.13 USD
- Market capitalization: 117.92 billion USD (as of September 18, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: November 17, 2026
